The global radiodermatitis market size reached US$ 481.9 Million in 2022. Looking forward, the publisher expects the market to reach US$ 597.9 Million by 2028, exhibiting a growth rate (CAGR) of 3.5% during 2023-2028.
Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.
Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.
Radiodermatitis Market Trends:
The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product and distribution channel.Breakup by Product:
Topical
- Corticosteroids
- Hydrophilic Creams
- Antibiotics
- Others
- Oral
Dressings
- Hydrogel and Hydrocolloid Dressings
- No Sting Barrier Film
- Honey Impregnated Gauze
- Silicone Coated Dressings
- Others
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Breakup by Region:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG.Key Questions Answered in This Report:
- What was the size of the global radiodermatitis market in 2022?
- What is the expected growth rate of the global radiodermatitis market during 2023-2028?
- What has been the impact of COVID-19 on the global radiodermatitis market?
- What are the key factors driving the global radiodermatitis market?
- What is the breakup of the global radiodermatitis market based on the product?
- What is the breakup of the global radiodermatitis market based on the distribution channel?
- What are the key regions in the global radiodermatitis market?
- Who are the key players/companies in the global radiodermatitis market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Radiodermatitis Market
6 Market Breakup by Product
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- 3M Company
- Bausch Health Companies Inc.
- Bayer AG
- BMG PHARMA S.p.A.
- Charles River Laboratories International Inc.
- ConvaTec Group plc
- Helsinn Healthcare SA
- ICON plc
- Integra LifeSciences
- Mölnlycke Health Care AB and Stratpharma AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 144 |
| Published | May 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 481.9 Billion |
| Forecasted Market Value ( USD | $ 597.9 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
